The DOI matches its Crossref record.
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
Open accessAbstract
OBJECTIVE About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable. METHODS We compared the new commercially available tumor marker HE4 with CA125 individually, in combination, within the risk of malignancy index (RMI) and the newly defined risk of malignancy algorithm (ROMA). Our prospectively-collected cohort of 160 patients consisted of healthy controls, benign diseases, and borderline tumors/adenocarcinomas of ovarian, tubal, peritoneal and endometrial origin. HE4 and CA125 were measured in serum using standardized ELISA. RESULTS Both markers showed similar diagnostic performance in the detection of EOC at clinically defined thresholds (CA125 35U/ml; HE4 70pM) but HE4 was not elevated in endometriosis. Comparison of non-malignant diagnoses (n=71) versus early stage ovarian and tubal cancers (n=19) revealed that HE4 and ROMA displayed the best diagnostic performance (AUC 0.86/0.87, specificity 85.9%/87.3% and sensitivity 78.9%/78.9%, respectively). Whilst RMICA125 detects peritoneal cancer better than all other models (AUC 0.99, specificity 97.2%, sensitivity 80.0%), there is no other detection benefit from RMI compared to HE4 alone or included in ROMA. CONCLUSIONS The major advantage of HE4 lies in its specificity and improved detection of borderline tumors and early stage ovarian and tubal cancers. HE4 is superior to CA125 with or without RMI and ROMA indices. However, we see no benefit from combining both markers in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Molecular Biomarkers for the Early Detection of Ovarian Cancer
Zhang, R., Siu, M. K. Y., Ngan, H. Y. S., & Chan, K. K. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231912041 · Cited by 283
ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors
Timmerman, D., Planchamp, F., Bourne, T., Landolfo, C., du Bois, A., Chiva, L., Cibula, D., Concin, N., Fischerova, D., Froyman, W., et al. (2021) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.23635 · Cited by 114
Human epididymis protein 4 (HE4) in benign and malignant diseases
Hertlein, L., Stieber, P., Kirschenhofer, A., Fürst, S., Mayr, D., Hofmann, K., Krocker, K., Nagel, D., Lenhard, M., & Burges, A. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0097 · Cited by 100
Metadata
- Authors
- Jacob, F., Meier, M., Caduff, R., Goldstein, D., Pochechueva, T., Hacker, N., Fink, D., & Heinzelmann-Schwarz, V.
- Venue
- Gynecologic Oncology
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 121
- Issue
- 3
- Pages
- 487-491
- ISSN
- 0090-8258 (ISSN-L)
- OpenAlex
- W2071541869
- Cited by
- 165
- References
- 0
- FWCI
- 20.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. https://app.cochat.ai/papers/10.1016/j.ygyno.2011.02.022
- The paper
- Jacob, F., Meier, M., Caduff, R., Goldstein, D., Pochechueva, T., Hacker, N., Fink, D., & Heinzelmann-Schwarz, V. (2011). No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2011.02.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.